Product Description
Lacosamide is used to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures. It acts on the central nervous system (CNS) to reduce the number and severity of seizures. However, this medicine cannot cure epilepsy and will only work to control seizures for as long as you continue to take it. (Sourced from: https://www.mayoclinic.org/drugs-supplements/lacosamide-oral-route/side-effects/drg-20072409?p=1)
Mechanisms of Action: Sodium Channel Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: Seizures
Known Adverse Events: Diplopia | Dizziness | Headache
Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czech Republic, Estonia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Latvia, Lithuania, Mexico, Moldova, Montenegro, Philippines, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, South Korea, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 22
Highest Development Phases
Phase 3: Acute Pain|Epilepsy|Epilepsy, Generalized|Epilepsy, Tonic-Clonic|Pain, Postoperative|Seizures
Phase 2: Healthy Volunteers|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EP0151 | P3 |
Unknown Status |
Epilepsy |
2025-08-31 |
|
| LENS | P2 |
Recruiting |
Epilepsy |
2025-08-04 |
32% |
| EP0151 | P3 |
Active, not recruiting |
Epilepsy |
2025-07-31 |
|
| 2020-001478-30 | P3 |
Active, not recruiting |
Epilepsy |
2025-07-05 |